The Effect of Vitamin D Supplementation on Psoriasis Severity - Full Text View Primary Outcome Measures: Secondary Outcome Measures: Physician Global Assessment (PGA) score [ Time Frame: Baseline and 4 months ] The difference in change between the vitamin D and placebo group in psoriasis severity measured by PGA score. Dermatology Quality of Life Index (DLQI) score [ Time Frame: Baseline, 8 weeks and 4 months ] The difference in change between the vitamin D and placebo group in self-reported
Dermatology (17), Anti-Obesity and Weight Loss (2) Psoriasis (16), Skin Diseases (1)
A Trial Comparing the Efficacy of Subcutaneous Injections of Brodalumab to Oral Administrations of Fumaric Acid Esters in Adults With Moderate to Severe Plaque Psoriasis - Full Text View The primary objective is to demonstrate added benefit of brodalumab versus a selected systemic comparator in treatment of moderate to severe plaque psoriasis in Germany in subjects who have not previously received systemic treatment for psoriasis.
AGN-242428 in the Treatment of Plaque Psoriasis - Full Text View Primary Outcome Measures: The percentage of participants achieving a reduction (improvement) in Psoriasis Area and Severity Index (PASI) score of ≥ 75% from baseline to Week 16 [ Time Frame: Baseline to Week 16 ] The PASI score ranges from 0-72 (with a higher score indicating greater severity of psoriasis), based on a combination of the severity (erythema, induration, and desquamation) of psoriasis and percentage of affected area.
A Study to Characterize Profile of Participant With Psoriatic Arthritis Depending on Whether Their Disease is Managed by a Dermatologist or by a Rheumatologist, and Starting Ustekinumab - Full Text View Number of Participants With Swelling of Joints at Baseline [ Time Frame: Baseline (Week 0) ] Participants with swollen 28-joints or 66/68-joints counts according to the practices will be evaluated.
Dermatology (8), Muscular and Skeletal Diseases (6), Immune System Diseases (5) Psoriasis (8), Psoriatic Arthritis (5), Arthralgia (4)
A Study on the Use of Laser Therapy to Treat Acne Vulgaris - Full Text View Primary Outcome Measures: Safety Assessment [ Time Frame: 14 months ] Evaluation of change in erythema, dryness/excessive scaling, itching, stinging/burning sensation, blistering, and pigmentary changes (hyperpigmentation/ hypopigmentation). Each variable is rated on a scale of increasing severity from 0 to 3.
Real-world Effectiveness of Adalimumab on Health Outcomes in Chinese Patients With Immune-Mediated Inflammatory Diseases - Full Text View Primary Outcome Measures: Change from baseline in EuroQoL-5 Dimension (EQ-5D) index score up to Week 24 [ Time Frame: From Week 0 to Week 24 ] The European quality of life-5 dimensions (EQ-5D) is a simple, easy to administer, standardized and self-report instrument for health status, which is applicable to a wide range of health conditions and treatment.
Study of Baricitinib (LY3009104) in Adults With Moderate to Severe Atopic Dermatitis - Full Text View Primary Outcome Measures: Secondary Outcome Measures: Proportion of Participants Achieving IGA of 0 or 1 with a ≥ 2 Point Improvement (Mid or Low Dose) [ Time Frame: 16 Weeks ] Proportion of participants achieving IGA of 0 or 1 with a ≥ 2 point improvement Proportion of Participants Achieving Eczema Area and Severity Index 75 (EASI75) [ Time Frame: 16 Weeks ] Proportion
Randomized Double-blind Study on the Benefit of Spironolactone for Treating Acne of Adult Woman. - Full Text View Acne vulgaris of adult woman has increased over the past 10 years; it affects currently 20% to 30% of adult women. The physiopathology of adult woman acne is distinguished from the teenager one by essentially 2 factors: hormonal factor with a peripheral hyperandrogenism coupled with an hypersensibility of cutaneous androgens receptors of these women.
Patient Centered Care Situation and Health-related Quality of Life by Patients With Psoriasis, Urticaria or Lupus - Full Text View Psoriasis, HRQL Patients with a medical diagnosis of Psoriasis were enclosed. Behavioral: HRQL Intervention of patient centered care situation and health-related quality of life of patients with Psoriasis, Urticaria or Lupus erythematodes from non-urban practices vs urban practises.
Dermatology (5), Immune System Diseases (3) Psoriasis (5), Urticaria (3)
An Open-label, Long-term Extension Study With Filgotinib in Active Psoriatic Arthritis. - Full Text View Primary Outcome Measures: Secondary Outcome Measures: Proportion of subjects achieving minimal disease activity (MDA). [ Time Frame: At each visit through Week 148. ] To assess the effect of filogotinib on MDA in PsA patients. Proportion of subjects achieving ACR20 response.